Pneumonic cancer is a dubious disease in the field of blood tumours, with complex clinical outcomes and often involving multi-system complications. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical outcomes, imaging, laboratory testing and pathological activation.
Platforms can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Individualised development of treatments for treatment and management of lung tumour cancer, usually including drug therapy, rehabilitation intervention, and regular follow-up to multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory treatment and precision medicine, many previously difficult to treat blood tumour diseases have been significantly improved.
Treatment needs to closely monitor efficacy and adverse reactions, adapting timely to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of lung cancer samples. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumours, to provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.